Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study

(2018) John B. Buse et al.   DIABETES CARE

HbA1cand Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study

(2018) Thomas Danne et al.   DIABETES CARE

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial

(2018) Chantal Mathieu et al.   DIABETES CARE

Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials

(2018) Tomohide Yamada et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis

(2018) Dana El Masri et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Development of SGLT1 and SGLT2 inhibitors

(2018) Timo Rieg et al.   DIABETOLOGIA

SGLT inhibitor adjunct therapy in type 1 diabetes

(2018) Rory J. McCrimmon et al.   DIABETOLOGIA

Sodium–Glucose Cotransporter–2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes

(2018) Caroline K. Kramer et al.   Annual Review of Medicine

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

(2018) Paresh Dandona et al.   DIABETES CARE

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

(2018) Julio Rosenstock et al.   DIABETES CARE

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

(2017) Satish K. Garg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

(2017) Paresh Dandona et al.   Lancet Diabetes & Endocrinology

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

(2016) Bo Ahrén et al.   DIABETES CARE

Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

(2016) Huilin Tang et al.   DIABETES OBESITY & METABOLISM

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes

(2015) Arthur T. Sands et al.   DIABETES CARE

Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes

(2015) Robert R. Henry et al.   DIABETES CARE

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)

(2015) T. R. Pieber et al.   DIABETES OBESITY & METABOLISM

SGLT2 Inhibitors May Predispose to Ketoacidosis

(2015) Simeon I. Taylor et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible adverse effects of SGLT2 inhibitors on bone

(2015) Simeon I Taylor et al.   Lancet Diabetes & Endocrinology

Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes

(2015) Bruce A. Perkins et al.   PLoS One

Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

(2014) Robert R. Henry et al.   DIABETES CARE

Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

(2014) Bruce A. Perkins et al.   DIABETES CARE

Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry

(2013) Ruth S. Weinstock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

(2012) S. Mudaliar et al.   DIABETES CARE